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Abstract
Background: A pathergy reaction is defined as a hyperreactivity of the skin in response to minimal trauma, which
is important in the diagnosis of Behçet’s disease (BD). However, a pathergy reaction may not be restricted to the
skin, and little is known about whether an invasive medical procedure can induce the reaction. Here we present a
pathergy reaction induced by renal biopsy, an invasive procedure.
Case presentation: A 46-year-old man who was diagnosed with IgA vasculitis (IgAV) at the age of 38 was treated
with prednisolone and mizoribine. However, complications such as common carotid arteritis or recurrent oral ulcer
suggested the possibility of another pathophysiology. Later, increasing urine protein developed, suggesting disease
aggravation. However, renal biopsy showed arteriosclerotic changes caused mainly by hypertension, negating
exacerbation. After renal biopsy, his renal dysfunction and body temperature fluctuated, and detailed examinations
revealed recurrent oral and genital ulcers and a folliculitis-like rash on his scrotum. Later, he complained of
myodesopsia caused by hemorrhage in the ocular fundus due to occlusive vasculitis. Complete BD was diagnosed
after development of the symptoms, and he was treated with prednisolone and colchicine.
Conclusion: Co-occurrence of BD with IgAV is very rare and may be associated with immune disorders.
Interestingly, a renal biopsy revealed BD, which was masked by the presence of IgAV, and elucidated the etiology
of the unexplainable symptoms. To the best of our knowledge, this is the first report of renal pathergy. This case
enlightens clinicians to the fact that not only a needle stimulation but also an invasive procedure can cause a
pathergy reaction.
Keywords: IgA vasculitis, Henoch-Schönlein purpura, Behçet’s disease, IgA nephritis, Renal biopsy, Pathergy
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Background
Behçet’s disease (BD) is characterized by recurrent oral
and genital ulceration, ocular disease, and several systemic
manifestations, including skin lesions, gastrointestinal
involvement, neurologic disease, vascular disease, and
arthritis [1]. BD can involve blood vessels of all sizes;
hence, most of its clinical manifestations are caused by
vasculitis [2]. In 1963, the first occurrence of proteinuria
and hematuria was reported in 13 of 65 BD patients [3].
Thereafter, many reports showed renal involvement with
BD [4, 5]. The association with IgA vasculitis (IgAV) and
BD is not clear [6–9]; few reports have shown a pathergy
reaction activated at other tissue sites [10], and we experi-
enced a rare case of pathergy reaction induced by renal
biopsy, an invasive procedure. To our knowledge, this is
the first report of a BD patient who experienced a renal
pathergy reaction.
Case presentation
A 46-year-old male was first referred to a nephrologist
at the age of 15 years due to proteinuria and hematuria.
Renal biopsy revealed IgA nephritis (IgAN). At 38 years,
his history of IgAN was complicated with abdominal
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pain and painful palpable purpura on his lower legs. A
skin biopsy revealed leukocytoclastic vasculitis. Thus, he
was diagnosed as having Henoch-Schönlein purpura
(IgAV). On the other hand, some of his complications
were unexplainable by the original disease alone, such as
common carotid arteritis and recurrent oral ulcer. Al-
though he was diagnosed with steroid-induced diabetes
mellitus at the age of 40, it was under control with
HbA1c levels approximately 7% on average; furthermore,
multiple examinations by an ophthalmologist revealed
no diabetic retinopathy. As a treatment for IgAV, oral
prednisolone (PSL) was started at 50 mg/day, and his
purpura and urine abnormalities resolved; PSL dose was
gradually reduced.
IgAV relapsed at the age of 45 with increasing urine
protein. Tonsillectomy plus triple methylprednisolone
pulse therapy did not ameliorate the urine protein aggra-
vation. Renal biopsy was performed and light micro-
scopic analysis of the specimen revealed 14 glomeruli; of
these, 2 were obsolescent, 4 were adherence lesions with
fibrous crescents showing previous active IgAV, and the
others exhibited only minor glomerular abnormalities.
Immunofluorescence staining was negative for IgA or
C3 in the glomeruli, and electron microscopy revealed
no evidence of an early sign of diabetic nephropathy
such as diffuse thickening of glomerular basement mem-
brane. As a result, no exacerbation of the original dis-
ease and no onset of other specific kidney lesions, such
as diabetic nephropathy, were observed (Figs. 1 and 2).
After the biopsy, intermittent fever developed and the
serum creatinine temporally changed from 0.68 to
2.26 mg/dl. In addition, a prolonged fever necessitated a
detailed laboratory analysis (Table 1). Microbacterial and
imaging inspections, including Ga-scintigraphy, could
not detect any inflammatory focus; however, a physical
examination revealed a folliculitis-like rash on his scro-
tum (Fig. 3). Ophthalmologic examination and gastros-
copy and colonoscopy tests yielded negative results. At
first, we diagnosed an incomplete type of BD, which was
treated with PSL. The increased dose of PSL failed to re-
lieve the fever and finger pain, and then, an ophthalmo-
logic reexamination revealed hemorrhage in the ocular
fundus (Fig. 4). In addition to the absence of microa-
neurysms, local filling defects of the vein were seen at
the area of retinal hemorrhage, suggesting BD-associated
vasculitis. After the diagnosis of complete-type of BD
was made, the PSL dose was increased to 30 mg daily.
Urinary protein levels subsequently improved along with
amelioration of BD, which supported that diabetes had
little contribution to the renal lesion, considering the ab-
sence of diabetic retinopathy and short history. Despite
tapering of the PSL, no exacerbation was observed with
the daily oral 8 mg of PSL and 1 mg of colchicine.
Conclusions
BD is a recurrent multisystem inflammatory disorder
characterized by vasculitis and arteritis [1, 2] and in-
volves blood vessels of all sizes [11–13]. Conversely,
Fig. 1 Light microscopic images of renal biopsy. a The biopsy highlighted 14 glomeruli, of which two were obsolescent, four were adherence
lesions with fibrous crescents showing previous active IgA vasculitis (periodic acid-silver methenamine stain; original magnification, ×200). b, c
Other glomeruli showed little hypertrophy and minor glomerular abnormalities (b periodic acid-silver methenamine stain; c Periodic acid-Schiff
stain; original magnification, ×600). d Tubulointerstitial atrophy developed and showed an arteriosclerotic lesion with hypertension and diabetes
(Masson trichrome stain; original magnification, ×40)
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IgAV is defined as vasculitis with IgA1-dominant
immune deposits; it affects small vessels, skin, and the
gastrointestinal tract and causes arthritis [14]. In this
case, IgAV caused abdominal pain and painful palpable
purpura; however, the patient presented at the same
time with bilateral common carotid arteritis on carotid
ultrasonography. The latter is explained by coexistence
of BD, which can affect large arteries. In addition, he
also had recurrent oral ulcers before the diagnosis of
IgAN, which also supports the coexistence of the two
diseases. However, the activity of BD was suppressed by
steroid therapy as an IgAV treatment but was coincidentally
activated by a pathergy reaction, which was identified dur-
ing a renal biopsy.
A pathergy reaction is defined as hyperreactivity of the
skin in response to minimal trauma [15]. This is import-
ant in the diagnosis of BD and is assigned 1 point based
on the International Criteria for BD, which classifies a pa-
tient scoring ≥4 points as having BD [16]. The pathergy
reaction was not restricted to the skin [10]; it also may be
associated with superficial thrombophlebitis induced by
venipuncture [17, 18], an erythematous lesion on the con-
junctiva after intravitreal corticosteroid injections [19],
anastomotic ulcers after surgical treatment of intestinal le-
sions [20], and aneurysm after vascular surgery [21, 22].
We could not confirm a clear presentation of inflamma-
tion on the puncture site in our case; however, renal
biopsy activated a pathergy reaction in the kidney, which
a b
Fig. 2 Immunofluorescence staining and electron microscopy of the renal biopsy. a Immunofluorescence staining for IgA and C3 showed
negative staining in the glomeruli (original magnification, ×600). b Electron microscopy revealed small electron-dense deposits (arrows) under the
basement membrane. In addition, diffuse thickening of glomerular basement membrane (GBM), which is known as an early ultrastructural
characterization of diabetic nephropathy, was not detected (sites of GBM not affected pointed in arrowheads) (original magnification, ×4000)
Table 1 Laboratory tests
Blood test γ-glutamyl transferase 25 IU/l anti-dsDNA Negative
White blood cells 10,800/μl Fasting blood glucose 117 mg/dl MPO-ANCA Negative
Hemoglobin 11.6 g/dl Hemoglobin A1c 7.4% PR3-ANCA Negative
Platelets 38.3 × 104/μl APTT 23.9 s anti-GBM Negative
Sodium 137.1 mEq/L PT-INR 1.05 HIV Negative
Potassium 3.6 mEq/L FDP 5.2 μg/ml HCV antibody Negative
Chloride 100.5 mEq/L C-reactive protein 1.87 mg/dl HBs antigen Negative
Calcium 9.0 mg/dl ESR 101 mm/h TPHA Negative
Phosphate 2.3 mg/dl IgA 330 mg/dl Urine test
Creatinine 0.74 mg/dl IgG 948 mg/dl pH 6.0
Urea Nitrogen 7.6 mg/dl IgM 87 mg/dl Occult blood Negative
Total protein 6.6 g/dl IgE 48 IU/ml Glucose Negative
Albumin 3.2 g/dl C3c 159 mg/dl White blood cells Negative
Lactate dehydrogenase 181 IU/l C4 51 mg/dl Urine protein 1.01 g/gCr
Aspartate aminotransferase 16 IU/l CH50 83 U/ml NAG 15.1 U/l
Alanine aminotransferase 25 IU/l Anti-nuclear antibody Negative β2-MG 1102 ng/ml
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Fig. 3 Physical examination. a Ulcers on the lower lip. b Ulcers on the tongue and buccal mucosa. c Genital ulcers. d Folliculitis-like rash on the scrotum
a
b c
Fig. 4 Ophthalmologic examination. a Fundus examination: hemorrhage in the peripheral retina (arrows). b, c Fluorescent fundus angiography. There
was no microaneurysm seen in diabetic retinopathy. The area of retinal hemorrhage and local filling defect of the vein are indicated by arrows
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is rich in blood vessels. We found that a renal biopsy itself
can reveal another vasculitis complication.
Albeit rarely, BD can complicate IgAV or IgAN;
only a limited number of articles have been reported
[6–9, 23, 24]; thus, there may be something unusual
about the coexistence. BD with renal involvement can
present in certain human leukocyte antigens (HLA)
differently from BD without renal involvement. Inter-
estingly, previous studies have reported that only one
of seven BD patients with renal involvement had
HLA-B51 [25], which is associated with an increased
risk of developing BD [26], while HLA-A2, A11, and
particularly B35 are associated with an increased risk
of IgAV [27]. The HLA types of blood lymphocytes
in our patient were A2, B35, B48, DR8, and DR12,
which suggests a high possibility of developing IgAV;
however, our patient did not have HLA-B51. A nega-
tive finding for HLA-B51, as observed in our case,
also may be a characteristic in BD patients with renal
involvement, and thus, HLA-B51 may not be helpful
in diagnosing BD with renal lesions.
BD can be diagnosed only by detailed physical examin-
ation; however, this is difficult when it is not suspected
or masked by presentation of other forms of vasculitis
or during immunosuppression treatment. Surprisingly, a
renal biopsy disclosed “masked” BD by inducing a renal
pathergy reaction; therefore, the etiology of common ca-
rotid arteritis and recurrent oral ulcer was unveiled be-
cause IgAV usually does not affect middle or large sized
arteries. If it had not been for the renal biopsy, we may
have failed to diagnose or treat the patient’s coexisting
BD. This case suggested that we should perform focused
history-taking and physical examinations when some
signs and symptoms in a patient cannot be explained
fully by one form of vasculitis, for example, IgAV.
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